[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 21 of about 21
1. Okazaki T, Ebihara S, Takahashi H, Asada M, Kanda A, Sasaki H: Macrophage colony-stimulating factor induces vascular endothelial growth factor production in skeletal muscle and promotes tumor angiogenesis. J Immunol; 2005 Jun 15;174(12):7531-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Macrophage colony-stimulating factor induces vascular endothelial growth factor production in skeletal muscle and promotes tumor angiogenesis.
  • Although M-CSF has been used for myelosuppression due to chemotherapy in patients with solid tumors, the effect of exogenous M-CSF on tumor angiogenesis has not been studied.
  • In this study we showed that M-CSF has the ability to accelerate solid tumor growth by enhancing angiogenesis with a novel mechanism.
  • M-CSF accelerated intratumoral vessel density in tumors inoculated into mice, although it did not accelerate the proliferation of malignant cells and cultured endothelial cells in vitro.
  • Moreover, M-CSF treatment induced the systemic elevation of vascular endothelial growth factor (VEGF).
  • VEGFR-2 kinase inhibitor significantly impaired the effect of M-CSF on tumor growth.
  • In vivo, M-CSF increased VEGF mRNA expression in skeletal muscles.
  • Even after treatment with carageenan and anti-CD11b mAb in mice, M-CSF increased VEGF production in skeletal muscles, suggesting that systemic VEGF elevation was attributed to skeletal muscle VEGF production.
  • These results suggest that M-CSF promotes tumor growth by increasing endothelial progenitor cells and activating angiogenesis, and the effects of M-CSF are largely based on the induction of systemic VEGF from skeletal muscles.
  • [MeSH-major] Carcinoma, Lewis Lung / blood supply. Carcinoma, Lewis Lung / immunology. Macrophage Colony-Stimulating Factor / physiology. Muscle, Skeletal / metabolism. Neovascularization, Pathologic / immunology. Vascular Endothelial Growth Factor A / biosynthesis
  • [MeSH-minor] Animals. Cell Line. Cell Proliferation. Endothelium, Vascular / immunology. Endothelium, Vascular / pathology. Humans. Male. Mice. Mice, Inbred C57BL. Microcirculation / immunology. Microcirculation / pathology. NIH 3T3 Cells. Neoplastic Cells, Circulating / immunology. Neoplastic Cells, Circulating / pathology. Protein-Serine-Threonine Kinases / metabolism. Proto-Oncogene Proteins / metabolism. Proto-Oncogene Proteins c-akt. Signal Transduction / immunology. Stem Cells / immunology. Stem Cells / pathology. Tumor Cells, Cultured

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15944252.001).
  • [ISSN] 0022-1767
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins; 0 / Vascular Endothelial Growth Factor A; 81627-83-0 / Macrophage Colony-Stimulating Factor; EC 2.7.11.1 / AKT1 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  •  go-up   go-down


2. Sarin H, Kanevsky AS, Fung SH, Butman JA, Cox RW, Glen D, Reynolds R, Auh S: Metabolically stable bradykinin B2 receptor agonists enhance transvascular drug delivery into malignant brain tumors by increasing drug half-life. J Transl Med; 2009;7:33
Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metabolically stable bradykinin B2 receptor agonists enhance transvascular drug delivery into malignant brain tumors by increasing drug half-life.
  • BACKGROUND: The intravenous co-infusion of labradimil, a metabolically stable bradykinin B2 receptor agonist, has been shown to temporarily enhance the transvascular delivery of small chemotherapy drugs, such as carboplatin, across the blood-brain tumor barrier.
  • It has been thought that the primary mechanism by which labradimil does so is by acting selectively on tumor microvasculature to increase the local transvascular flow rate across the blood-brain tumor barrier.
  • In this study we investigated the systemic actions of labradimil, as well as other bradykinin B2 receptor agonists with a range of metabolic stabilities, in context of the local actions of the respective B2 receptor agonists on the blood-brain tumor barrier of rodent malignant gliomas.
  • METHODS: Using dynamic contrast-enhanced MRI, the pharmacokinetics of gadolinium-diethyltriaminepentaacetic acid (Gd-DTPA), a small MRI contrast agent, were imaged in rodents bearing orthotopic RG-2 malignant gliomas.
  • Baseline blood and brain tumor tissue pharmacokinetics were imaged with the 1st bolus of Gd-DTPA over the first hour, and then re-imaged with a 2nd bolus of Gd-DTPA over the second hour, during which normal saline or a bradykinin B2 receptor agonist was infused intravenously for 15 minutes.
  • Metabolically stable bradykinin B2 agonists, methionine-lysine-bradykinin and labradimil, had differential effects on the transvascular flow rate of Gd-DTPA across the blood-brain tumor barrier.
  • Both methionine-lysine-bradykinin and labradimil increased the blood half-life of Gd-DTPA sufficiently enough to increase significantly the tumor tissue Gd-DTPA area under the time-concentration curve.
  • CONCLUSION: Metabolically stable bradykinin B2 receptor agonists, methionine-lysine-bradykinin and labradimil, enhance the transvascular delivery of small chemotherapy drugs across the BBTB of malignant gliomas by increasing the blood half-life of the co-infused drug.
  • The selectivity of the increase in drug delivery into the malignant glioma tissue, but not into normal brain tissue or skeletal muscle tissue, is due to the inherent porous nature of the BBTB of malignant glioma microvasculature.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / blood supply. Brain Neoplasms / drug therapy. Drug Delivery Systems. Receptor, Bradykinin B2 / agonists
  • [MeSH-minor] Animals. Blood Pressure / drug effects. Blood-Brain Barrier / drug effects. Dose-Response Relationship, Drug. Drug Stability. Gadolinium DTPA / blood. Gadolinium DTPA / pharmacokinetics. Glioma / blood supply. Half-Life. Infusions, Intravenous. Muscle, Skeletal / drug effects. Muscle, Skeletal / metabolism. Rats. Rats, Inbred F344. Time Factors

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Pharmacokinet. 2001;40(2):105-23 [11286321.001]
  • [Cites] J Pharmacol Exp Ther. 2001 Feb;296(2):632-41 [11160652.001]
  • [Cites] Int J Cancer. 2002 Mar 1;98(1):29-35 [11857381.001]
  • [Cites] Lancet. 2002 Mar 23;359(9311):1011-8 [11937180.001]
  • [Cites] Vascul Pharmacol. 2002 Jun;38(6):323-37 [12529927.001]
  • [Cites] Methods Mol Med. 2003;89:177-90 [12958420.001]
  • [Cites] J Neurosurg. 2003 Oct;99(4):728-37 [14567609.001]
  • [Cites] Prog Drug Res. 2003;61:39-78 [14674608.001]
  • [Cites] Cancer Chemother Pharmacol. 2004 Sep;54(3):206-12 [15156345.001]
  • [Cites] J Cell Biol. 1968 May;37(2):244-76 [5656394.001]
  • [Cites] Am J Physiol. 1971 Feb;220(2):371-6 [5099786.001]
  • [Cites] J Neurol Sci. 1972 Sep;17(1):29-39 [4341504.001]
  • [Cites] Br J Exp Pathol. 1976 Aug;57(4):419-30 [183804.001]
  • [Cites] Pharmacol Rev. 1980 Mar;32(1):1-46 [7015371.001]
  • [Cites] Kidney Int. 1981 Nov;20(5):615-20 [6283229.001]
  • [Cites] Cancer Res. 1983 Jul;43(7):3368-73 [6850641.001]
  • [Cites] J Neurosurg. 1983 Jun;58(6):874-84 [6854380.001]
  • [Cites] J Neurosurg. 1983 Aug;59(2):304-10 [6864299.001]
  • [Cites] J Natl Cancer Inst. 1984 Jan;72(1):145-50 [6582294.001]
  • [Cites] AJR Am J Roentgenol. 1984 Mar;142(3):619-24 [6607655.001]
  • [Cites] AJR Am J Roentgenol. 1984 Mar;142(3):625-30 [6607656.001]
  • [Cites] J Nucl Med. 1985 Jan;26(1):72-6 [3965655.001]
  • [Cites] Invest Radiol. 1988 Sep;23 Suppl 1:S264-6 [3198359.001]
  • [Cites] Cancer Res. 1989 Jul 1;49(13):3506-12 [2731172.001]
  • [Cites] Magn Reson Med. 1990 Oct;16(1):117-31 [2255233.001]
  • [Cites] Magn Reson Med. 1991 Feb;17(2):357-67 [2062210.001]
  • [Cites] Br J Cancer. 1992 Mar;65(3):347-50 [1558786.001]
  • [Cites] Br J Cancer. 1992 Aug;66(2):323-30 [1503906.001]
  • [Cites] Kidney Int. 1993 Sep;44(3):545-50 [8231026.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jun 15;29(3):473-9 [8005802.001]
  • [Cites] J Cereb Blood Flow Metab. 1994 Sep;14(5):862-70 [8063881.001]
  • [Cites] Life Sci. 1994;55(10):735-49 [8072371.001]
  • [Cites] Pharm Res. 1994 Nov;11(11):1673-6 [7870689.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Mar 14;92(6):1846-50 [7892189.001]
  • [Cites] Cancer Res. 1996 Sep 1;56(17):3998-4005 [8752170.001]
  • [Cites] Magn Reson Imaging. 1996;14(3):235-41 [8725189.001]
  • [Cites] Neurosurgery. 1996 Jul;39(1):125-33; discussion 133-4 [8805148.001]
  • [Cites] Comput Biomed Res. 1996 Jun;29(3):162-73 [8812068.001]
  • [Cites] Immunopharmacology. 1996 Jun;33(1-3):270-8 [8856161.001]
  • [Cites] Cancer Res. 1998 Jan 1;58(1):159-65 [9426072.001]
  • [Cites] Neurosurgery. 1999 Feb;44(2):351-9; discussion 359-60 [9932889.001]
  • [Cites] Cancer Gene Ther. 1999 Jan-Feb;6(1):14-20 [10078959.001]
  • [Cites] Eur Radiol. 1999;9(5):998-1004 [10370005.001]
  • [Cites] J Magn Reson Imaging. 1999 Sep;10(3):223-32 [10508281.001]
  • [Cites] J Natl Cancer Inst. 1951 Oct;12(2):399-421 [14889251.001]
  • [Cites] J Pharmacol Exp Ther. 1965 Apr;148:117-22 [14279175.001]
  • [Cites] Invest Radiol. 2005 Nov;40(11):715-24 [16230904.001]
  • [Cites] Neoplasia. 2007 Jul;9(7):546-55 [17710157.001]
  • [Cites] Acta Radiol. 2008 Mar;49(2):172-9 [18300142.001]
  • [Cites] J Transl Med. 2008;6:80 [19094226.001]
  • [Cites] Immunopharmacology. 1999 Sep;43(2-3):255-63 [10596861.001]
  • [Cites] Exp Neurol. 2000 Jan;161(1):234-44 [10683290.001]
  • [Cites] Cancer Chemother Pharmacol. 2000;45(4):284-90 [10755316.001]
  • [Cites] AJNR Am J Neuroradiol. 2000 May;21(5):891-9 [10815665.001]
  • [Cites] J Pharmacol Exp Ther. 2000 Jun;293(3):903-11 [10869391.001]
  • [Cites] J Magn Reson Imaging. 2000 Dec;12(6):991-1003 [11105041.001]
  • [Cites] Pharm Res. 2000 Oct;17(10):1212-9 [11145226.001]
  • [Cites] J Pharmacol Exp Ther. 2001 Feb;296(2):623-31 [11160651.001]
  • [Cites] Neurol Res. 2001 Jun;23(4):379-87 [11428519.001]
  • (PMID = 19439100.001).
  • [ISSN] 1479-5876
  • [Journal-full-title] Journal of translational medicine
  • [ISO-abbreviation] J Transl Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Receptor, Bradykinin B2; K2I13DR72L / Gadolinium DTPA
  • [Other-IDs] NLM/ PMC2689161
  •  go-up   go-down


3. Dobashi Y, Suzuki S, Sato E, Hamada Y, Yanagawa T, Ooi A: EGFR-dependent and independent activation of Akt/mTOR cascade in bone and soft tissue tumors. Mod Pathol; 2009 Oct;22(10):1328-40
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EGFR-dependent and independent activation of Akt/mTOR cascade in bone and soft tissue tumors.
  • To gain the insight into the involvement of signaling mediated by the mammalian target of rapamycin (mTOR) in the phenotype and biological profiles of tumors and tumor-like lesions of the bone and soft tissue, we analyzed the expression and phosphorylation (activation) of mTOR and its correlation with the status of upstream and downstream modulator proteins Akt, p70S6-kinase (S6K), and eukaryotic initiation factor 4E-binding protein 1 (4E-BP1), which we refer to collectively as mTOR cassette proteins.
  • Immunohistochemical analysis of 140 cases showed activation of Akt in 55% (61% in malignant and 27% in benign), and mTOR expression in 61% (66% in malignant and 39% in benign).
  • The preponderance of mTOR activation was found in tumors of peripheral nerve sheath (malignant peripheral nerve sheath tumor and schwannoma), skeletal muscle origin (rhabdomyosarcoma), and in those exhibiting epithelial nature (chordoma and synovial sarcoma).
  • We conclude that mTOR-mediated signaling proteins function not only in the proliferation of the tumor cells, but also in the differentiation and/or maintenance of morphological phenotypes in tumors of rhabdomyoblastic and nerve sheath cell origin.
  • Overall, these results suggest that inhibitors of mTOR cassette may be useful as novel components of combined chemotherapy for a defined subset of bone and soft tissue sarcomas.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / analysis. Bone Neoplasms / enzymology. Phosphoproteins / analysis. Protein Kinases / analysis. Proto-Oncogene Proteins c-akt / analysis. Receptor, Epidermal Growth Factor / analysis. Ribosomal Protein S6 Kinases, 70-kDa / analysis. Signal Transduction. Soft Tissue Neoplasms / enzymology
  • [MeSH-minor] Cell Proliferation. Enzyme Activation. Humans. Immunoblotting. Immunohistochemistry. Mutation. Neoplasm Staging. Phosphorylation. Prognosis. TOR Serine-Threonine Kinases

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19648884.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / EIF4EBP1 protein, human; 0 / Phosphoproteins; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.1 / Ribosomal Protein S6 Kinases, 70-kDa
  •  go-up   go-down


Advertisement
4. Pérez Serna AG, Moreno Hoyos LF, Ramírrez Valdivia S: [Conservative surgery as an alternative treatment of a knee osteosarcoma in the presence of a pathological fracture]. Acta Ortop Mex; 2009 Nov-Dec;23(6):351-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Conservative surgery as an alternative treatment of a knee osteosarcoma in the presence of a pathological fracture].
  • [Transliterated title] Cirugía de salvamento como alternativa en el tratamiento de osteosarcoma de rodilla ante la presencia de fractura en terreno patológico.
  • INTRODUCTION: classical osteosarcoma is defined as a very malignant spindle cell sarcoma, characterized by the production of osteoid matrix, it is the most common primary malignant bone tumor.
  • Factors involved include those related with the skeletal growth and development, pathological fractures, and very young patients who are still growing.
  • Conservative surgery is inappropriate; however, preoperative chemotherapy and a good choice of conservative treatment are an alternative.
  • MATERIAL AND METHODS: a 15-year-old male patient presented at the orthopedics service with a diagnosis of a pathological fracture in the distal third of the right femur and a tumor in the lateral aspect of the knee, with pain and limitation of gait.
  • Treatment consisted of conservative surgery with broad tumor resection involving 18 cm of the femur, resection of the vastus medialis and vastus lateralis, release of the femoral bundle, the popliteal and sciatic nerves, as well as placement of a modular stryker tumor prosthesis, with knee replacement.
  • At 5 months there is no evidence of tumor relapse, the patient can walk properly and has recovered the strength.
  • DISCUSSION: this is a case salvage surgery to treat a pathological fracture resulting from a malignant bone tumor.
  • We think that staging is essential to select the treatment.
  • In the case presented herein a comprehensive management is fundamental to the success of conservative treatment.
  • [MeSH-minor] Adolescent. Adult. Age Factors. Gait. Humans. Limb Salvage. Male. Quadriceps Muscle / surgery. Sex Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Osteosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20377001.001).
  • [ISSN] 2306-4102
  • [Journal-full-title] Acta ortopédica mexicana
  • [ISO-abbreviation] Acta Ortop Mex
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


5. Punt SE, Eary JF, O'Sullivan J, Conrad EU: Fluorodeoxyglucose positron emission tomography in leiomyosarcoma: imaging characteristics. Nucl Med Commun; 2009 Jul;30(7):546-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fluorodeoxyglucose positron emission tomography in leiomyosarcoma: imaging characteristics.
  • OBJECTIVE: Leiomyosarcoma, a malignant neoplasm of smooth muscle, accounts for 7% of the sarcomas.
  • These tumors, which are derived from mesenchymal tissues, are difficult to diagnose, and treatment options remain controversial.
  • The relatively rare incidence of this soft tissue sarcoma subtype has limited the number of patients available for studies and research.
  • This study examines whether the imaging characteristics of positron emission tomography (PET) with radiolabeled fluorodeoxyglucose (FDG) provide a reliable, noninvasive means to predict tumor behavior in patients with leiomyosarcomas.
  • METHODS: [18F]-FDG-PET was performed on the tumors of participating patients before the neoadjuvant chemotherapy or resection, and a maximum tumor standard uptake value (SUVmax) was calculated.
  • RESULTS: The SUVmax was correlated with tumor grade (P=0.001) and tumor size as greatest dimension (P=0.004).
  • Analysis of these data indicated the potential effectiveness of FDG-PET imaging in predicting tumor grade.
  • CONCLUSION: In leiomyosarcoma, the SUVmax from FDG-PET is a likely predictor of tumor behavior.
  • The results of this study suggest that a large (by greatest dimension) intermediate grade tumor is expected to have the same predicted outcome as a high-grade tumor and should be treated in the same manner, as they share the same prognosis by definition of tumor grade.
  • Improvements made in the clinical treatment of leiomyosarcomas by use of FDG-PET imaging data may lead to an increase in patient survival.

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Bone Joint Surg Am. 2004;86-A Suppl 2:98-104 [15691114.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8828-34 [16314643.001]
  • [Cites] Clin Cancer Res. 1998 May;4(5):1215-20 [9607579.001]
  • [Cites] Ann Surg. 2000 Apr;231(4):500-5 [10749609.001]
  • [Cites] Clin Cancer Res. 2000 Apr;6(4):1279-87 [10778952.001]
  • [Cites] Ann Surg. 2001 Oct;234(4):540-7; discussion 547-8 [11573047.001]
  • [Cites] Skeletal Radiol. 2001 Oct;30(10):543-59 [11685477.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Sep;29(9):1149-54 [12192559.001]
  • [Cites] J Nucl Med. 2003 Jun;44(6):930-42 [12791822.001]
  • [Cites] Gynecol Oncol. 2004 Feb;92(2):701-4 [14766270.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2004 Feb;31(2):189-95 [15129700.001]
  • [Cites] Ir J Med Sci. 2011 Dec;180(4):889-91 [19184604.001]
  • [Cites] Clin Orthop Relat Res. 2009 Jun;467(6):1605-11 [19048352.001]
  • [Cites] Wien Klin Wochenschr. 2007;119(17-18):557-60 [17943409.001]
  • [Cites] Ann Thorac Surg. 2007 May;83(5):1826-9; discussion 1829-30 [17462407.001]
  • [Cites] Kyobu Geka. 2006 Dec;59(13):1191-6 [17163213.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2006 Nov;33(11):1290-5 [16832631.001]
  • (PMID = 19440162.001).
  • [ISSN] 1473-5628
  • [Journal-full-title] Nuclear medicine communications
  • [ISO-abbreviation] Nucl Med Commun
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA065537-13; United States / NCI NIH HHS / CA / R01 CA065537; United States / NCI NIH HHS / CA / R01 CA 65537; United States / NCI NIH HHS / CA / R01 CA065537-13
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Other-IDs] NLM/ NIHMS121746; NLM/ PMC2752415
  •  go-up   go-down


6. Belaabidia B, Sellami S, Hamdaoui R, Essadki B: [Primary malignant non-Hodgkin skeletal muscle lymphoma: a case report]. Rev Chir Orthop Reparatrice Appar Mot; 2002 Sep;88(5):518-21
Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary malignant non-Hodgkin skeletal muscle lymphoma: a case report].
  • [Transliterated title] Lymphome malin non-hodgkinien primitif du muscle squelettique: à propos d'un cas.
  • BACKGROUND: Malignant non-Hodgkin lymphoma (NHL) is rarely encountered in soft tissue.
  • The differential diagnosis with other soft tissue tumors, particularly sarcoma, is difficult.
  • At computed tomography, the mass measured 17x14x7 cm and was situated in the biceps femoris.
  • Tumor biopsy demonstrated diffuse malignant small B-cell lymphomatous-plasma cell proliferation.
  • Wide resection was followed by chemotherapy.
  • DISCUSSION: Primary NHL of skeletal muscle is usually observed in elderly subjects, principally in thigh muscles.
  • Magnetic resonance imaging and computed tomography visualize characteristic features.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Muscle Neoplasms / diagnosis
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Biopsy. Chemotherapy, Adjuvant. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Immunohistochemistry. Thigh. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Primary malignant lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12399719.001).
  • [ISSN] 0035-1040
  • [Journal-full-title] Revue de chirurgie orthopédique et réparatrice de l'appareil moteur
  • [ISO-abbreviation] Rev Chir Orthop Reparatrice Appar Mot
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


7. Laffosse JM, Gomez-Brouchet A, Molinier F, Chiron P, Roché H, Puget J: A case of malignant primary non-Hodgkin's lymphoma in skeletal muscle treated by exclusive chemotherapy. Joint Bone Spine; 2009 Jan;76(1):86-8
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of malignant primary non-Hodgkin's lymphoma in skeletal muscle treated by exclusive chemotherapy.
  • Malignant non-Hodgkin's lymphoma (MNHL) is a frequent tumour but a primary intra-muscular location is exceptional.
  • Standard treatment combines wide surgical removal with chemotherapy and radiotherapy.
  • The treatment was purely medical and conservative with chemotherapy after a multidisciplinary oncological discussion.
  • Three years after the treatment, the general state of health is excellent with no signs of local or remote recurrence.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / pathology. Muscle Neoplasms / drug therapy. Muscle Neoplasms / pathology. Muscle, Skeletal / pathology
  • [MeSH-minor] Aged. Antibodies, Monoclonal / administration & dosage. Biomarkers, Tumor / analysis. Cyclophosphamide / therapeutic use. Disease-Free Survival. Doxorubicin / therapeutic use. Female. Humans. Magnetic Resonance Imaging. Prednisone / therapeutic use. Thigh / pathology. Treatment Outcome. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Primary malignant lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18993104.001).
  • [ISSN] 1778-7254
  • [Journal-full-title] Joint, bone, spine : revue du rhumatisme
  • [ISO-abbreviation] Joint Bone Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


8. Milicic D, Juretic A, Bulum J, Saric N, Bisof V, Jelic I, Jelasic D: Primary malignant fibrous histiocytoma of the heart with skeletal muscles metastases. J Card Surg; 2007 Nov-Dec;22(6):513-6
Genetic Alliance. consumer health - Malignant fibrous histiocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant fibrous histiocytoma of the heart with skeletal muscles metastases.
  • Malignant fibrous histiocytoma is an extremely rare primary malignant tumor of the heart.
  • The prognosis is poor with an average survival time of one year.
  • We report a case of recurrent left atrial malignant fibrous histiocytoma initially misdiagnosed as myxoma.
  • The patient underwent repeated surgical resections followed by chemotherapy.
  • Despite adjuvant chemotherapy, 18 months after initial diagnosis, definitive tumor relapse in left atrium was diagnosed.
  • This is the 48th case of primary cardiac fibrous malignant histiocytoma reported in the literature.
  • [MeSH-major] Histiocytoma, Malignant Fibrous / diagnosis. Muscle Neoplasms / diagnosis. Muscle, Skeletal / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18039217.001).
  • [ISSN] 0886-0440
  • [Journal-full-title] Journal of cardiac surgery
  • [ISO-abbreviation] J Card Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


9. Orui H, Yamakawa M, Ishikawa A, Tsuchiya T, Ogino T: Malignant intramuscular forearm tumor with overwhelming squamous element. Pathol Int; 2000 Jul;50(7):574-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant intramuscular forearm tumor with overwhelming squamous element.
  • Squamous cell carcinoma (SCC) arising in the skeletal muscle is rare.
  • A case of a 19-year-old female patient with an intramuscular forearm tumor showing a histopathologically overwhelming squamous element is presented.
  • A malignant spindle cell component was not detected.
  • Neither evidence of another primary site nor skin lesion over the tumor was found and no metastatic lesion was detected in the 5 years since the appearance of the mass.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Muscle Neoplasms / pathology
  • [MeSH-minor] Actins / analysis. Actins / genetics. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Axilla. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Drug Therapy, Combination. Female. Forearm / pathology. Humans. Lymph Node Excision. Lymph Nodes / surgery. Magnetic Resonance Imaging. Mitomycin / administration & dosage. Oncogene Proteins, Fusion / analysis. Oncogene Proteins, Fusion / genetics. Peplomycin / administration & dosage. RNA, Messenger / metabolism. RNA, Neoplasm / analysis. Reverse Transcriptase Polymerase Chain Reaction. Treatment Outcome. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10886743.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] AUSTRALIA
  • [Chemical-registry-number] 0 / Actins; 0 / Oncogene Proteins, Fusion; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / SYT-SSX fusion protein; 50SG953SK6 / Mitomycin; 56H9L80NIZ / Peplomycin; 5J49Q6B70F / Vincristine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


10. Marchal JA, Boulaiz H, Rodríguez-Serrano F, Peran M, Carrillo E, Vélez C, Domínguez J, Gómez-Vidal JA, Campos J, Gallo MA, Espinosa A, Aránega A: 5-fluorouracil derivatives induce differentiation mediated by tubulin and HLA class I modulation. Med Chem; 2007 May;3(3):233-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neoplastic cells exhibit defects in their ability to differentiate; therefore, differentiation therapy represents a viable option to control cancer growth and progression.
  • Rhabdomyosarcomas (RMS), a malignant tumor of skeletal muscle, is the most common soft tissue sarcoma in children and is characterized by its poor response to cytotoxic treatment and significant morbidity.
  • Since modulation of alpha-tubulin and human leukocyte antigen (HLA) class I expression has been detected during malignant transformation, we analyzed in this study the expression pattern of both kinds of proteins after the treatment with 5-FU derivatives in the human RMS RD cell line.
  • [MeSH-major] Cell Differentiation / drug effects. Fluorouracil / analogs & derivatives. Fluorouracil / pharmacology. Histocompatibility Antigens Class I / genetics. Tubulin / genetics
  • [MeSH-minor] Antimetabolites, Antineoplastic / chemistry. Antimetabolites, Antineoplastic / pharmacology. Cell Line. Gene Expression Regulation / drug effects. Humans. Microtubules / drug effects. Rhabdomyosarcoma / drug therapy. Rhabdomyosarcoma / pathology. Structure-Activity Relationship

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17504194.001).
  • [ISSN] 1573-4064
  • [Journal-full-title] Medicinal chemistry (Shāriqah (United Arab Emirates))
  • [ISO-abbreviation] Med Chem
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Histocompatibility Antigens Class I; 0 / Tubulin; U3P01618RT / Fluorouracil
  •  go-up   go-down


11. Hartman A, van den Bos C, Stijnen T, Pieters R: Decrease in peripheral muscle strength and ankle dorsiflexion as long-term side effects of treatment for childhood cancer. Pediatr Blood Cancer; 2008 Apr;50(4):833-7
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decrease in peripheral muscle strength and ankle dorsiflexion as long-term side effects of treatment for childhood cancer.
  • BACKGROUND: This study investigated muscle strength, passive ankle dorsiflexion, and their association with motor performance in children after treatment for acute lymphoblastic leukemia, Wilms tumor, B-non-Hodgkin lymphoma, and malignant mesenchymal tumors.
  • PROCEDURE: Muscle strength was assessed with a hand-held dynamometer and ankle dorsiflexion with a goniometer in 92 and 64 survivors, respectively.
  • Mean time since completing treatment: 3.3 years.
  • RESULTS: Muscle strength of the survivors was reduced in ankle dorsiflexors on both sides (P < 0.001), wrist dorsiflexors on the non-dominant side (P < 0.001), and pinch grip on the non-dominant (P = 0.001) and dominant side (P = 0.01).
  • Movement-ABC percentile score was affected by pinch grip strength on the non-dominant (P < 0.004), and dominant side (P = 0.024) but not by strength of other muscle groups or by passive ankle dorsiflexion.
  • CONCLUSION: Peripheral muscle strength and ankle dorsiflexion are reduced in the long-term in children treated for cancer with chemotherapy.
  • However, neither decreased muscle strength nor reduced ankle dorsiflexion could completely explain reduced scores on the movement-ABC.
  • [MeSH-major] Ankle / physiology. Antineoplastic Agents / adverse effects. Motor Activity / drug effects. Muscle Strength / drug effects. Neoplasms / drug therapy
  • [MeSH-minor] Child. Dexamethasone / administration & dosage. Female. Humans. Male. Muscle Strength Dynamometer. Muscle, Skeletal / drug effects. Prednisone / administration & dosage. Range of Motion, Articular / drug effects. Time. Vincristine / administration & dosage. Vincristine / adverse effects

  • Genetic Alliance. consumer health - Childhood Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 17763466.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; VB0R961HZT / Prednisone
  •  go-up   go-down


12. Chigurupati R, Alfatooni A, Myall RW, Hawkins D, Oda D: Orofacial rhabdomyosarcoma in neonates and young children: a review of literature and management of four cases. Oral Oncol; 2002 Jul;38(5):508-15
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Rhabdomyosarcoma (RMS) is an aggressive malignant skeletal muscle neoplasm arising from embryonal mesenchyme.
  • It accounts for over 50% of all pediatric soft tissue sarcomas.
  • The head and neck region is the most common site for this tumor in children.
  • Neonatal presentation of this tumor is rare.
  • Three of the four cases were alveolar RMS and one was botryoid sub-type of embryonal RMS.
  • Three patients were treated with a combination of surgery, chemotherapy and radiation, while the patient with botryoid RMS was treated with surgery and chemotherapy only.
  • [MeSH-major] Facial Neoplasms / therapy. Mouth Neoplasms / therapy. Rhabdomyosarcoma / therapy
  • [MeSH-minor] Child. Combined Modality Therapy. Fatal Outcome. Female. Follow-Up Studies. Humans. Infant. Infant, Newborn. Male. Neoplasm Staging. Prognosis

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12110348.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 33
  •  go-up   go-down


13. Scher RL: Role of nitric oxide in the development of distant metastasis from squamous cell carcinoma. Laryngoscope; 2007 Feb;117(2):199-209
Hazardous Substances Data Bank. (L)-ARGININE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Metastasis, the dissemination of malignant cells to distant sites, remains one of the most significant factors responsible for death from cancer.
  • Recent studies have shown some improvement in the rate of distant metastasis (DM) with the addition of chemotherapy to surgery and radiation for treatment of head and neck squamous cell carcinoma (HNSCC).
  • However, diagnosis and treatment at an early stage ultimately leads to a better prognosis.
  • The prediction of which patients will develop metastasis and the selection of treatment most effective at preventing and treating metastasis remains dependent on an incomplete understanding of prognostic factors and the biological and molecular basis for metastatic development.
  • The findings will result in better understanding of the metastatic process for HNSCC, with the potential to develop and implement therapies that could prevent and treat metastasis in patients.
  • The cremaster muscle and liver, used as arterial and venous flow models, were tested to determine whether IVVM was useful for the study of human HNSCC interactions with the microcirculation.
  • [MeSH-minor] Animals. Arginine / pharmacology. Cell Adhesion / drug effects. Cell Adhesion / physiology. Cell Line, Tumor. Cell Movement / physiology. Cell Shape / physiology. Disease Models, Animal. Enzyme Inhibitors / pharmacology. Fluorescent Dyes. Humans. Interleukin-1 / physiology. Liver Circulation / physiology. Mice. Mice, Inbred BALB C. Mice, Nude. Microcirculation / physiology. Microscopy, Video. Muscle, Skeletal / blood supply. Nitric Oxide Synthase / antagonists & inhibitors. Rats. Rats, Nude. omega-N-Methylarginine / pharmacology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17277613.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Endothelium-Dependent Relaxing Factors; 0 / Enzyme Inhibitors; 0 / Fluorescent Dyes; 0 / Interleukin-1; 27JT06E6GR / omega-N-Methylarginine; 31C4KY9ESH / Nitric Oxide; 94ZLA3W45F / Arginine; EC 1.14.13.39 / Nitric Oxide Synthase
  •  go-up   go-down


14. Malerba M, Garofalo A: [A rare case of nerve-sheath sarcoma with rhabdomyoblastic differentiation (malignant triton tumor)]. Tumori; 2003 Jul-Aug;89(4 Suppl):246-50

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A rare case of nerve-sheath sarcoma with rhabdomyoblastic differentiation (malignant triton tumor)].
  • [Transliterated title] Un raro caso di sarcoma delle guaine nervose a differenziazione rabdomioblastica (malignant Triton tumor).
  • Malignant peripheral nerve sheath tumors (MPNST) are spindle-cell sarcomas that appear in a setting of neurofibroma or schwannoma or are associated with peripheral nerves or demonstrate nerve sheath differentiation.
  • Malignant triton tumor (MTT) is a subtype of MPNST that also contain tissue with skeletal muscle differentiation (embryonal, plemorphic and botryoid rhabdomyosarcoma).
  • A xifopubic laparotomy was performed: the tumor appeared to be localized, well-capsulated and strictly associated to the lumbar and sacral nervous radicles (L4, L5, S1) without evidence of invasion.
  • The tumor was completely resected with sparing of the psoas muscle and the lumbar plexus through a subperineural dissection technique.
  • Postoperative pathologic findings showed evidence for a trition tumor.
  • Sarcoma arising in anatomic site other than extremity and superficial trunk are often more difficult to control because of anatomic constraints, delayed disease presentation, proximity to neurovascular and osseous structures and toxicity for normal adjacent tissues that limits the use of adequate radiation doses.
  • In contrast to the benefit most patients with high grade soft tissue sarcomas of the extremities receive from adjuvant radiation and chemotherapy, these modalities have been of little value for retroperitoneal tumors.
  • Current chemotherapy for retroperitoneal sarcomas is ineffective.
  • Local adjuvant therapy such as intraperitoneal chemotherapy or experimental immunotherapy seems to be attractive in theory, but needs further investigations through prospective randomized multicentric trials.
  • In conclusion, to date aggressive surgical management remains the most effective modality for selected primary and recurrent retroperitoneal soft tissue sarcomas including MPNSTs and the subtype MTT.
  • Patients with incomplete resection and other risk factors such as younger age and high grade tumors may be suitable candidates for investigational adjuvant therapy.
  • [MeSH-minor] Adult. Axilla. Cell Differentiation. Humans. Knee. Male. Mediastinal Neoplasms / pathology. Mediastinal Neoplasms / surgery. Muscles / pathology. Soft Tissue Neoplasms / pathology. Soft Tissue Neoplasms / surgery. Spinal Nerve Roots / pathology. Spinal Nerve Roots / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12903608.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Ludwig K: [Musculoskeletal lymphomas]. Radiologe; 2002 Dec;42(12):988-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary lymphomas of bone or skeletal muscle are rare entities.
  • Primary manifestations of Hodgkin's disease in bone or skeletal muscle are rarities.
  • Primary non-Hodgkin's lymphomas of skeletal muscle are rarities as well.
  • Their differential diagnosis includes -- depending on the patient's age -- Ewing's sarcoma,malignant fibrous histiocytoma,metastases of small cell tumors and osteomyelitis.Further differential diagnoses are the peripheral primitive neuroectodermal tumor (PNET), osteosarcoma, eosinophilic granuloma and fibrosarcoma.
  • Treatment of primary non-Hodgkin's lymphomas uses combinations of chemotherapy and radiation therapy.
  • Operative treatment is reserved for the treatment of complications.
  • [MeSH-major] Bone Neoplasms / diagnosis. Hodgkin Disease / diagnosis. Lymphoma, Non-Hodgkin / diagnosis. Magnetic Resonance Imaging. Muscle Neoplasms / diagnosis. Tomography, X-Ray Computed
  • [MeSH-minor] Bone and Bones / pathology. Humans. Muscle, Skeletal / pathology. Neoplasm Staging. Prognosis. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12486552.001).
  • [ISSN] 0033-832X
  • [Journal-full-title] Der Radiologe
  • [ISO-abbreviation] Radiologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 0
  •  go-up   go-down


16. Chi AC, Barnes JD, Budnick S, Agresta SV, Neville B: Rhabdomyosarcoma of the maxillary gingiva. J Periodontol; 2007 Sep;78(9):1839-45
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Rhabdomyosarcoma is a malignant neoplasm of primitive mesenchyme exhibiting skeletal muscle differentiation.
  • The tissue was boggy and tender on palpation.
  • Many of the tumor cells exhibited abundant eosinophilic cytoplasm.
  • Immunohistochemical stains showed the tumor cells to be positive for desmin, myogenin, and myogenic differentiation 1 (MyoD1).
  • The patient was treated by surgical resection with postoperative chemotherapy and radiation.
  • The patient had no evidence of disease at a follow-up examination 1 month after completion of therapy.
  • Over several decades, a multidisciplinary treatment approach that includes surgical removal if resectable, in combination with multiagent chemotherapy and possibly radiation therapy, has improved survival rates.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17760557.001).
  • [ISSN] 0022-3492
  • [Journal-full-title] Journal of periodontology
  • [ISO-abbreviation] J. Periodontol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 51
  •  go-up   go-down


17. Yang JY, Kim JM: Small cell extraskeletal osteosarcoma. Orthopedics; 2009 Mar;32(3):217
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Extraskeletal osteosarcoma is a rare malignant mesenchymal neoplasm that accounts for <4% of all osteosarcomas and approximately 1.2% of all soft tissue sarcomas.
  • Among the extraskeletal osteosarcomas, the small cell type is extremely rare.
  • This article describes a 31-year-old man who had small cell extraskeletal osteosarcoma arising from the semimembranosus muscle.
  • The results were reported as a malignant small round cell tumor, consistent with an extraskeletal Ewing's sarcoma or primitive neuroectodermal tumor.
  • Immunohistochemically, the tumor showed reactivity with antibodies against CD99 and neuron-specific enolase, but not with antibodies against S100 protein, CD138, alpha smooth muscle actin, chromogranin, Ki-67, leukocyte common antigen, epithelial membrane antigen, CD30, or desmin.
  • The patient refused neoadjuvant chemotherapy.
  • Adjuvant chemotherapy was performed using doxorubicin, ifosfamide, and cisplatin together with a total of 60 Gy of radiation therapy.
  • We performed chest computed tomography, magnetic resonance imaging, and positron emission tomography-computed tomography.
  • [MeSH-major] Muscle Neoplasms / pathology. Osteosarcoma / pathology. Sarcoma, Small Cell / pathology
  • [MeSH-minor] Adult. Antigens, CD / analysis. Biomarkers, Tumor / analysis. Cell Adhesion Molecules / analysis. Combined Modality Therapy. Disease-Free Survival. Humans. Male. Muscle, Skeletal / pathology

  • Genetic Alliance. consumer health - Osteosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19309043.001).
  • [ISSN] 1938-2367
  • [Journal-full-title] Orthopedics
  • [ISO-abbreviation] Orthopedics
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / CD99 protein, human; 0 / Cell Adhesion Molecules
  •  go-up   go-down


18. Marchal JA, Núñez MC, Aránega A, Gallo MA, Espinosa A, Campos JM: Acyclonucleosides, modified seco-nucleosides, and salicyl- or catechol-derived acyclic 5-fluorouracil O,N-acetals: antiproliferative activities, cellular differentiation and apoptosis. Curr Med Chem; 2009;16(9):1166-83
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The goal of cancer chemotherapy with classical drugs - the destruction of the tumor cells - is often complicated by significant toxicity.
  • As an alternative, induced differentiation modulates the cell programme by transforming malignant cells into mature cells with no proliferative potential.
  • Our data demonstrate that (+/-)-1-{[3-(2-hydroxyethoxy)-1-isopropoxy]propyl}-5-fluorouracil inhibits proliferation, induces myogenic differentiation, increases the expression of proteins specifically present in normally differentiated skeletal muscle cells, and modifies the adhesion capacity of these cells against the rhabdomyosarcoma cell line RD.
  • The MCF-7 cells trea-ed with (+/-)-(Z)-43 caused an increase in the lipid content over control cells after 3 days of treatment.
  • Our results suggest that there may be significant potential advantages in the use of this new differentiating agent for the treatment of breast cancer.
  • [MeSH-major] Acetals / pharmacology. Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Cell Differentiation / drug effects. Nucleosides / pharmacology
  • [MeSH-minor] Breast Neoplasms / drug therapy. Cell Line, Tumor. Cell Proliferation / drug effects. Fluorouracil / chemistry. Humans

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19275619.001).
  • [ISSN] 0929-8673
  • [Journal-full-title] Current medicinal chemistry
  • [ISO-abbreviation] Curr. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Acetals; 0 / Antineoplastic Agents; 0 / Nucleosides; U3P01618RT / Fluorouracil
  • [Number-of-references] 68
  •  go-up   go-down


19. Collin AC, Chekaroua K, Delaporte T, Droz JP, Peix JL, Delay E: [Anaplastic thyroid carcinoma: aggressive radical resection and cervical reconstruction. A case report]. Ann Chir; 2006 Dec;131(10):631-5
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • STUDY AIM: Anaplastic carcinoma of the thyroid is a rare but highly malignant tumor.
  • The goal of this study was to present the case of a patient who underwent a multimodal treatment and to analyze prognosis factors.
  • The initial surgical procedure was a total thyroidectomy extended to the anterior cervical skin associated to bilateral neck dissection.
  • Management was then supplemented by radiotherapy and chemotherapy.
  • RESULTS: This patient is free of tumor 9 years after this multimodal management.
  • CONCLUSION: Anaplastic carcinoma is one of more aggressive neoplasm affecting humans.
  • This case report suggests that multimodality therapy, including surgery, chemotherapy and radiotherapy may offer hope for long-term survival.
  • [MeSH-minor] Chemotherapy, Adjuvant. Disease-Free Survival. Female. Follow-Up Studies. Humans. Middle Aged. Muscle, Skeletal / transplantation. Radiotherapy, Adjuvant. Skin Transplantation / methods

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16824476.001).
  • [ISSN] 0003-3944
  • [Journal-full-title] Annales de chirurgie
  • [ISO-abbreviation] Ann Chir
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


20. Lee SC, Wu CJ, Wu PY, Huang YL, Wu CW, Tao MH: Inhibition of established subcutaneous and metastatic murine tumors by intramuscular electroporation of the interleukin-12 gene. J Biomed Sci; 2003 Jan-Feb;10(1):73-86
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Intramuscular EP of pIL-12 resulted in complete regression or substantial inhibition of 38C13 B-cell lymphoma, whereas pIL-12 delivered by gene gun or intramuscular injection without EP showed little therapeutic effect.
  • Impressive antitumor activity by intramuscular EP was also demonstrated in animals with advanced malignant disease.
  • At day 14 after 38C13 tumor inoculation, all animals were found to carry large tumors and to have metastases; without treatment, most died within a week.
  • Moreover, animals that were previously cured of 38C13 tumors by in vivo EP treatment significantly suppressed tumor growth when challenged 60 days later.
  • Together, these results show that intramuscular electrotransfer of the IL-12 gene may represent a simple and effective strategy for cancer treatment.
  • [MeSH-major] Genetic Therapy / methods. Interleukin-12 / administration & dosage. Neoplasm Metastasis / prevention & control. Neoplasms, Experimental / therapy
  • [MeSH-minor] Animals. Dose-Response Relationship, Drug. Electroporation. Female. Lung Neoplasms / prevention & control. Lung Neoplasms / secondary. Mice. Mice, Inbred Strains. Muscle, Skeletal. Survival Rate. Time Factors. Treatment Outcome. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 National Science Council, ROC and S. Karger AG, Basel
  • (PMID = 12566989.001).
  • [ISSN] 1021-7770
  • [Journal-full-title] Journal of biomedical science
  • [ISO-abbreviation] J. Biomed. Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 187348-17-0 / Interleukin-12
  •  go-up   go-down


21. Rossi S, Fletcher CD: Angiosarcoma arising in hemangioma/vascular malformation: report of four cases and review of the literature. Am J Surg Pathol; 2002 Oct;26(10):1319-29
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant change in a benign vascular tumor is exceedingly rare, and there have been only five previously reported convincing cases.
  • MRI disclosed the presence of two separate soft tissue masses in both thighs in one patient.
  • Radiotherapy/chemotherapy was given in all cases.
  • Two patients were disease free 2 and 14 months after surgery and two developed metastases.
  • Grossly, the tumors were described as frankly hemorrhagic masses or as firm, whitish areas with hemorrhagic nodules and were centered in skeletal muscle in three cases.
  • In three cases the benign and the malignant components were variably intermixed, whereas in one case the HVM was mainly located at the edge of the malignant tumor.
  • [MeSH-major] Hemangioma / pathology. Hemangiosarcoma / pathology. Soft Tissue Neoplasms / pathology

  • Genetic Alliance. consumer health - Hemangioma.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12360047.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement